Context Therapeutics LLC

Context Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is dedicated to improving the lives of women living with cancer. It engages in developing advanced small molecule and immunotherapy treatments to transform care for hormone-driven breast and gynecological cancers. The firm's robust clinical program for candidate onapristone extended release (ONA-XR) comprises three Phase 2 clinical trials and one Phase 1b/2 clinical trial in hormone-driven breast, ovarian and endometrial cancer, as well as two Phase 0 biomarker pharmacodynamic trials in breast cancer. Its ONA-XR is a novel, first-in-class small molecule under development as a complete antagonist of the progesterone receptor, a key unchecked mechanism in hormone-driven women?s cancers. The company was founded by Martin Lehr and Felix Kim in April 2015 and is headquartered in Philadelphia, PA.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Company reports preliminary ONA-XR data from two ongoing Phase 2 trials

Context Therapeutics® Reports Third Quarter 2022 Operating and Financial Results

Philadelphia, Pennsylvania--(Newsfile Corp. - October 20, 2022) - Context Therapeutics Inc. (NASDAQ: CNTX) ("Context" or the "Company"), a women's oncology company developing novel treatments for breast and gynecologic cancers, today announced the Company will participate in The ThinkEquity Conference, taking place on October 26, 2022, at The Mandarin Oriental Hotel in New York City.Context CEO Martin Lehr will present at 9:30 a.m. ET on October 26. Interested parties can register to attend here.

Context Therapeutics to Participate in the ThinkEquity Conference

Context Therapeutics (NASDAQ:CNTX) Inc has announced a plan to streamline its resources and extend its cash runway into 2024 as market pressures put a strain on biotechnology companies. The women's oncology company plans to defer noncritical R&D activities, reduce future overhead and infrastructure expenditures and push forward with its onapristone extended release (ONA-XR) ELONA Phase 1b/2 clinical trial and Claudin 6 (CLDN6) program.

Context Therapeutics CEO charts path for fiscal stability into 2024, tightens focus on Phase 1b ELONA breast cancer trial

Company to focus resources on advancing ONA-XR ELONA Phase 1b/2 clinical trial and on advancing CLDN6xCD3 bispecific antibody toward IND Company to focus resources on advancing ONA-XR ELONA Phase 1b/2 clinical trial and on advancing CLDN6xCD3 bispecific antibody toward IND

Context Therapeutics® Amends Cash Guidance, Extends Runway into Q1 2024

PHILADELPHIA, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women's oncology company developing novel treatments for breast and gynecological cancers, today announced that Chief Executive Officer Martin Lehr will participate in a fireside chat during the H.C. Wainwright 24th Annual Global Investment Conference taking place virtually and in-person September 12-14, 2022, in New York City. The fireside chat will be available on demand for conference participants beginning September 12 at 7 a.m. ET.

Context Therapeutics® to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

Context Therapeutics (NASDAQ:CNTX) Inc has reported results for the second quarter that revealed ample cash on hand, giving the company scope to advance its pipeline programs. As of June 30, 2022, the Philadelphia-based women's oncology company developing treatments for breast and gynecological cancers, had cash, equivalents, and restricted cash which totaled $42.9 million.

Context Therapeutics ends 2Q with strong $42.9M cash runway to advance pipeline programs

Announced new clinical trial collaboration with Menarini Group to evaluate ONA-XR plus elacestrant in metastatic breast cancer

Context Therapeutics® Reports Second Quarter 2022 Operating and Financial Results

Preclinical data support the potential of ONA-XR plus estrogen receptor degraders in endocrine resistant disease models Context to initiate Phase 1b/2 clinical trial in Q4 2022 PHILADELPHIA and FLORENCE, Italy , Aug. 2, 2022 /PRNewswire/ -- Context Therapeutics Inc. ("Context" or the "Company") (Nasdaq: CNTX), a women's oncology company developing small molecule and immunotherapy treatments for breast and gynecological cancers, and The Menarini Group ("Menarini") today announced a clinical trial collaboration and supply agreement for Menarini's oral selective estrogen receptor degrader (SERD), elacestrant. This agreement will support the upcoming Phase 1b/2 ELONA clinical proof-of-concept trial evaluating onapristone extended release (ONA-XR), an oral progesterone receptor (PR) antagonist, in combination with elacestrant in estrogen receptor positive (ER+), PR+ HER2- metastatic breast cancer (mBC) patients who have previously been treated with a CDK4/6 inhibitor.

Context Therapeutics and The Menarini Group Announce Clinical Trial Collaboration and Supply Agreement to Evaluate ONA-XR and Elacestrant Combination

Context Therapeutics (NASDAQ:CNTX) Inc and The Menarini Group have announced a clinical trial collaboration and supply agreement for Menarini's oral selective estrogen receptor degrader (SERD), elacestrant. The women's oncology company said the agreement will support the upcoming Phase 1b/2 ELONA clinical proof-of-concept trial evaluating onapristone extended release (ONA-XR), an oral progesterone receptor (PR) antagonist, in combination with elacestrant in estrogen receptor positive (ER+), PR+ HER2- metastatic breast cancer (mBC) patients who have previously been treated with a CDK4/6 inhibitor.

Context Therapeutics collaborates with Menarini Group to evaluate ONA-XR and elacestrant combination

Context Therapeutics (NASDAQ:CNTX) Inc announced that it has ended its first quarter of 2022 with $45.7 million in cash and equivalents as of March 31, which the company says should be sufficient to fund its operations into 2024. The women's oncology company also noted that 2022 looks to be a “pivotal year” as it anticipates reporting preliminary data of ONA-XR from ongoing Phase 2 trials in breast, ovarian, and endometrial cancers later in the year.

Context Therapeutics ends 1Q with $45.7M as it gears up for 'pivotal' 2022

Abstract on results of the monotherapy portion of Phase 2 ONA-XR clinical trial in granulosa cell tumors of the ovary accepted for oral presentation at the 2022 ASCO Annual Meeting

Context Therapeutics® Reports First Quarter 2022 Operating and Financial Results

Context Therapeutics (NASDAQ:CNTX) Inc has told investors that an abstract on the results of the monotherapy portion of its ongoing Phase 2 trial of lead candidate onapristone extended release (ONA-XR) in granulosa cell tumors of the ovary was accepted for oral presentation at the 2022 American Society of Clinical Oncology (ASCO) annual meeting. The meeting takes place from June 3-7, 2022 at the McCormick Place Convention Center in Chicago, Illinois.

Context Therapeutics announces poster presentation at upcoming 2022 ASCO annual meeting

Context Therapeutics (NASDAQ:CNTX) Inc announced what it called “encouraging” preclinical data from two pipeline programs, including in vivo combination and immunomodulation data evaluating onapristone extended release (ONA-XR), the company's lead clinical program.  Context said the lead clinical-stage oral progesterone receptor (PR) antagonist ONA-XR demonstrated strong efficacy across multiple PR+ solid tumor models.

Context Therapeutics reveals “encouraging” preclinical data from two cancer-treating pipeline programs

Lead clinical-stage oral progesterone receptor (PR) antagonist ONA-XR demonstrates strong efficacy across multiple PR+ solid tumor models

Context Therapeutics® Announces Encouraging Preclinical Data from Two Programs to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2022

PHILADELPHIA, April 06, 2022 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women's oncology company developing small molecule and immunotherapy treatments for breast and gynecological cancers, today announced that Chief Executive Officer Martin Lehr will participate virtually in two investor conferences in April 2022. Details of the events are as follows:

Context Therapeutics® to Participate in Two April 2022 Investor Conferences

Context Therapeutics Inc said it closed 2021 with a balance sheet of nearly $50 million. As of December 31, 2021, the women's oncology company developing small molecule and immunotherapy treatments for breast and gynecological cancers said its cash, cash equivalents, and restricted cash were $49.7 million -- compared to $0.3 million at the end of 2020.

Context Therapeutics closes 2021 with balance sheet of nearly $50M

Investor R&D event on April 13 th to highlight new preclinical data to be presented at AACR Annual Meeting

Context Therapeutics® Reports Full Year 2021 Operating and Financial Results

Context to host webinar with AACR presenters on Wednesday, April 13, 2022, at 11 a.m. ET Context to host webinar with AACR presenters on Wednesday, April 13, 2022, at 11 a.m. ET

Context Therapeutics® Announces Acceptance of Five Abstracts to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2022

Edison Investment Research has initiated coverage of Context Therapeutics (NASDAQ:CNTX) Inc with a valuation of $134.9 million or $8.45 per share. The shares are currently trading at $1.81.

Edison Investment Research initiates coverage of Context Therapeutics Inc with valuation of $8.45 per share

If 2021 was a pivotal year for Context Therapeutics (NASDAQ:CNTX) Inc, 2022 promises to be even more so.  Fresh from a US$31.25 million fundraise and last October's debut on the Nasdaq, the clinical-stage biopharmaceutical company focused on bettering the lives of women living with cancer, is developing advanced small molecule and immunotherapy treatments to transform care for hormone-driven breast and gynecological cancers.

Context Therapeutics prepares for a busy 2022 as it advances women's oncology treatments

PHILADELPHIA, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women's oncology company developing small molecule and immunotherapy treatments for breast and gynecological cancers, today announced that Chief Executive Officer Martin Lehr will deliver a corporate presentation during the Sachs 15th Annual European Life Sciences CEO Forum taking place virtually March 1-2, 2022.

Context Therapeutics® to Participate in the Sachs 15th Annual European Life Sciences CEO Forum

Flotek Industries

Palisade Bio

Senseonics Holdings

Are these on your list of the best penny stocks to buy right now? Here's what analysts think The post 4 Penny Stocks To Buy Now According To Analysts, Targets Over 300% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

4 Penny Stocks To Buy Now According To Analysts, Targets Over 300%

Context Therapeutics Inc is beefing up its research and development team with the appointments of two new executives. Christopher Beck will take on the role of senior vice president of operations and Mark Fletcher will be the firm's new vice president of research and development, according to a statement from the company.

Context Therapeutics adds two new executives to strengthen its research and development team

Company names Christopher Beck as SVP, Operations and Mark Fletcher, Ph.D., as VP, R&D Company names Christopher Beck as SVP, Operations and Mark Fletcher, Ph.D., as VP, R&D

Context Therapeutics® Strengthens Research & Development Team

PHILADELPHIA, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women's oncology company developing small molecule and immunotherapy treatments for breast and gynecological cancers, today announced that Chief Executive Officer Martin Lehr will participate virtually in two investor conferences in January 2022.

News for Context Therapeutics LLC Stock (CNTX)